Trial Profile
Efficacy of brentuximab vedotin in allogeneic stem cell transplanted patients with relapsed/refractory hodgkin lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 21 Sep 2016 New trial record